Our findings suggest that CKS2 may play a critical role in the progression of BL and DLBCL and provide evidence for the potential therapeutic application of combining CKS2‐shRNA and etoposide agents in the treatment of BL and DLBCL. This evidence concerns the gene CKS2 and diffuse large B-cell lymphoma.